Biotech Stocks Reviews
- 2023 Names & Themes To Watch
Thu, Jan 19
Below are a few names to watch, each divided into a different segment. Value: Atyr Pharma (LIFE)Atyr · more » - NK Sentiment and Impact on Affimed
Mon, Jan 9
Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the · more » - Looking Back on 2022 Name Updates
Fri, Dec 30
Ending a rather difficult 2022 with a few quick notes on names that were written about this year. · more » - Notes from KOL on AFM13+NK ASH2022 Data
Fri, Dec 23
Yesterday, Slingshot Insights had a call with a lymphoma KOL on Affimed’s (AFMD) AFM13+NK data that · more » - Affimed Scraps Mono AFM13 To Focus on Combinations
Mon, Dec 12
Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both · more » - Astria Runs Ahead of Phase 1 Readout
Thu, Dec 1
Astria (ATXS)expects preliminary results from Phase 1a trial of STAR-0215 by year end 2022. The trial · more » - Jounce Announces Yet Another Delay
Thu, Dec 1
Jounce Announces Yet Another DelayJounce will be reporting their Phase 2 proof of concept data for their · more » - Affimed Reports Early & Promising Activity for AFM24 Combination
Thu, Dec 1
Affimed jumped yesterday after reporting unexpected activity of AFM24+atezolizumab in EGFR+ solid · more » - Affimed Announced Artiva as NK Cell Partner
Fri, Nov 4
Affimed announced an early peek at updated AFM13+NK data that will be presented at ASH conference on · more »